Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study

Study limitation reported by the research below: “Level of evidence assigned as 3 (non-randomized interventional study) due to the open-label, single-arm design without a comparator arm.”